Advertisement
Research Article| Volume 142, ISSUE 1, P30-37, July 2016

Download started.

Ok

Non-surgical management of ovarian cancer: Prevalence and implications

  • David I. Shalowitz
    Correspondence
    Corresponding author at: Division of Gynecologic Oncology, 3rd Floor West, 3400 Civic Center Boulevard, Philadelphia, PA 19104, United States.
    Affiliations
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, United States
    Search for articles by this author
  • Andrew J. Epstein
    Affiliations
    Division of General Internal Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA, United States

    Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, United States
    Search for articles by this author
  • Emily M. Ko
    Affiliations
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, United States
    Search for articles by this author
  • Robert L. Giuntoli II
    Affiliations
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, United States
    Search for articles by this author

      Highlights

      • 18% of EOC patients in the NCDB did not receive surgical treatment.
      • 22% of elderly patients with advanced disease received only systemic treatment; 23% were untreated.
      • It is unclear how often deviation from best-practices guidelines is clinically appropriate.

      Abstract

      Purpose

      To identify prevalence, correlates and survival implications of non-surgically managed epithelial ovarian cancer (EOC).

      Methods

      The National Cancer Database (NCDB) was queried for EOC cases between 2003 and 2011. Type of treatment, survival data, reasons for non-surgical treatment, clinicopathologic and process-based factors were collected. Logistic regression identified independent predictors of surgical treatment; Cox proportional hazards regression modeled association between time to death and receipt of surgery.

      Results

      172,687 of 210,667 patients (82%) received surgical treatment for EOC. 95% of patients treated non-surgically had stage III, stage IV or unknown stage disease. The reason for non-surgical treatment was unclear in 80% of cases. Black race and uninsurance were significantly associated with non-surgical treatment. Median survival time was 57.4 months (95% CI: 56.8–57.9) for surgery with or without systemic treatment compared to 11.9 months (95% CI: 11.6–12.2) for systemic treatment alone and 1.4 months (95% CI: 1.3–1.4) for no treatment. Relative to surgical treatment, the adjusted hazard ratio for death associated with systemic treatment alone was 1.9 (p < 0.001); hazard ratio for untreated patients was 4.7 (p < 0.001). Among 29,921 patients older than 75 with Stage III/IV disease, 21.5% received only systemic treatment; 22.8% were entirely untreated.

      Conclusion

      18% of EOC patients in the NCDB did not receive surgical treatment. These patients experienced significantly worsened survival. Prospective investigation is needed to determine how often apparent deviation from best-practices guidelines is clinically appropriate. Non-surgically treated patients may be at risk for poor access to gynecologic oncology care and deserve further study.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: ovarian cancer, version 2.2015.

        • Cliby W.A.
        • Powell M.A.
        • Al-Hammadi N.
        • et al.
        Ovarian cancer in the United States: contemporary patterns of care associated with improved survival.
        Gynecol. Oncol. 2014; https://doi.org/10.1016/j.ygyno.2014.10.023
        • Goff B.A.
        • Matthews B.J.
        • Larson E.H.
        • et al.
        Predictors of comprehensive surgical treatment in patients with ovarian cancer.
        Cancer. 2007; 109: 2031-2042https://doi.org/10.1002/cncr.22604
        • Erickson B.K.
        • Martin J.Y.
        • Shah M.M.
        • Straughn J.M.
        • Leath C.A.
        Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center.
        Gynecol. Oncol. 2014; 133: 142-146https://doi.org/10.1016/j.ygyno.2014.02.006
        • Thrall M.M.
        • Gray H.J.
        • Symons R.G.
        • Weiss N.S.
        • Flum D.R.
        • Goff B.A.
        Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.
        Gynecol. Oncol. 2011; 122: 100-106https://doi.org/10.1016/j.ygyno.2011.03.022
        • Urban R.R.
        • He H.
        • Alfonso R.
        • Hardesty M.M.
        • Gray H.J.
        • Goff B.A.
        Ovarian cancer outcomes: predictors of early death.
        Gynecol. Oncol. 2016; 140: 474-480https://doi.org/10.1016/j.ygyno.2015.12.021
        • Trillsch F.
        • Woelber L.
        • Eulenburg C.
        • et al.
        Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium.
        J. Ovarian Res. 2013; 6: 42https://doi.org/10.1186/1757-2215-6-42
        • Byrom J.
        • Widjaja E.
        • Redman C.W.E.
        • Jones P.W.
        • Tebby S.
        Can pre-operative computed tomography predict resectability of ovarian carcinoma at primary laparotomy?.
        BJOG. 2002; 109 (http://www.ncbi.nlm.nih.gov/pubmed/12013156. Accessed November 24, 2015): 369-375
        • Jung D.C.
        • Kang S.
        • Kim M.J.
        • Park S.Y.
        • Kim H.B.
        Multidetector CT predictors of incomplete resection in primary cytoreduction of patients with advanced ovarian cancer.
        Eur. Radiol. 2010; 20: 100-107https://doi.org/10.1007/s00330-009-1533-0
        • Narasimhulu D.M.
        • Khoury-Collado F.
        • Chi D.S.
        Radical surgery in ovarian cancer.
        Curr. Oncol. Rep. 2015; 17: 16https://doi.org/10.1007/s11912-015-0439-z
        • Cowan R.A.
        • O'Cearbhaill R.E.
        • Gardner G.J.
        • et al.
        Is it time to centralize ovarian cancer Care in the United States?.
        Ann. Surg. Oncol. 2015; https://doi.org/10.1245/s10434-015-4938-9